Jefferies Conference Highlights How Biotech’s Rollercoaster Ride Will Continue Into 2024
Survey shows long-term optimism but fears that 2024 will be another hard slog for those biotechs with dwindling cash resources.
Survey shows long-term optimism but fears that 2024 will be another hard slog for those biotechs with dwindling cash resources.